BostonGene to Present Four AI-Driven Research Abstracts at AACR 2025, Highlighting Precision Oncology and Drug Development Advances

BostonGene, a pioneering company in AI-driven molecular and immune profiling, has announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled from April 25 to 30 at McCormick Place Convention Center in Chicago, Illinois. The company will present four abstracts that highlight the capabilities of its integrated multiomic platform, designed to optimize drug trials, accelerate drug development, and improve patient outcomes in precision oncology. Core Characters and Key Participants: - Ferran Prat, PhD, JD: BostonGene’s Chief Commercial Officer, who will speak at an AACR educational session on academic entrepreneurship. - BostonGene’s Research Team: In collaboration with leading academic and medical institutions, such as MD Anderson Cancer Center, Repare Therapeutics, and Hokkaido University Hospital. Abstract Presentations: 1. Abstract Number: 1101 - Title: A novel machine learning classifier for SCLC transcriptional subtypes - Date and Time: Sunday, April 27, 2:00 PM - 5:00 PM - Presenter: Carl Gay, MD, PhD, from MD Anderson Cancer Center. - Findings: BostonGene developed gradient-boosting machine learning models to refine small cell lung cancer (SCLC) subtypes. The models showed high performance metrics during validation, potentially enhancing clinical impact. Abstract Number: 5308 Title: Pan-cancer analysis of TRIM37 copy-number and development of fit-for-screening in situ hybridization tools Date and Time: Sunday, April 27, 2:00 PM - 5:00 PM Presenter: J.D. Schonhoft, PhD, from Repare Therapeutics. Findings: BostonGene’s whole-exome sequencing (WES) platform analyzed over 12,000 adult solid tumor samples, revealing high TRIM37 expression in many patients. The study also introduced sensitive DNA- and RNA-based in situ hybridization (ISH) methods, crucial for examining clinical biomarkers. Abstract Number: 2036 Title: Transcriptomic immune signatures and reconstructed immune cell types associated with pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer Date and Time: Monday, April 28, 9:00 AM - 12:00 PM Presenter: Tomohiro Oshino, MD, from Hokkaido University Hospital. Findings: BostonGene’s tumor microenvironment (TME) subtyping and cell deconvolution tools were used to reconstruct the TME in triple-negative breast cancer (TNBC) patients. The results showed that patients with immune-enriched TME were more likely to achieve a pathological complete response after neoadjuvant chemotherapy, indicating the platform's potential in predicting treatment response. Abstract Number: 5047 Title: Enhancing germline variant calling: Adjustment with tumor samples to filter low-confidence variants from clonal hematopoiesis Date and Time: Tuesday, April 29, 9:00 AM - 12:00 PM Presenter: Artur Baisangurov, MS, from BostonGene. Findings: BostonGene’s WES analysis of 2,078 cancer patients led to the development of a filtering method that improves the accuracy of germline variant reports. This approach helps identify and exclude low-confidence variants caused by clonal hematopoiesis, streamlining genetic report quality control. Additional Events: - Educational Session on Academic Entrepreneurship: Ferran Prat will speak at an educational session on April 26, 8:00 AM - 9:30 AM, covering topics such as intellectual property rights, capital raising, and commercialization pathways. This session aims to bridge knowledge gaps and empower researchers to bring their innovations to patient care. - BrightEdge Entrepreneurs (BEE) Dinner: BostonGene is partnering with the American Cancer Society to host the BEE Dinner on April 28. The event will feature eight cancer-focused startups from the BEE Program, providing a platform for underrepresented scientific entrepreneurs to receive mentorship, investor access, and early-stage funding. Impact and Evaluation: Industry insiders commend BostonGene’s integrated multiomic platform for its comprehensive and high-resolution capabilities in tumor characterization and treatment optimization. The use of AI and multiomic data in precision oncology is seen as a significant step forward in both clinical care and translational research. BostonGene’s contributions to the AACR Annual Meeting underscore its commitment to advancing cancer research through innovative technologies and collaborations. Company Profile: BostonGene Corporation is a leading company in AI-driven molecular and immune profiling for oncology. It operates from a CLIA-certified and CAP-accredited clinical laboratory, offering diagnostic and treatment recommendation solutions that personalize care for patients. The company’s platform integrates advanced molecular and immune profiling with clinical data to inform trial design and optimize patient selection. For more information, visit www.BostonGene.com.